Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:CELU NASDAQ:CYTH NASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.36$1.37$0.86▼$3.36$82.38M0.14326,589 shs116,149 shsCELUCelularity$2.55-35.3%$2.95$1.00▼$5.22$61.07M0.81169,961 shs860,867 shsCYTHCyclo Therapeutics$0.72$0.72$0.55▼$1.45$23.72M-0.57585,177 shsN/AVTGNVistaGen Therapeutics$3.52+5.4%$2.71$1.90▼$3.60$107.99M0.55262,488 shs679,125 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%-9.93%+0.74%+30.77%-50.36%CELUCelularity0.00%+2.60%+26.28%+69.83%+27.92%CYTHCyclo Therapeutics0.00%0.00%0.00%0.00%-3.62%VTGNVistaGen Therapeutics0.00%+10.23%+14.38%+39.75%-4.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.7124 of 5 stars3.54.00.00.01.71.70.6CELUCelularity0.6341 of 5 stars2.02.00.00.01.11.70.0CYTHCyclo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVTGNVistaGen Therapeutics1.2375 of 5 stars0.03.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.00Buy$7.00416.61% UpsideCELUCelularity 0.00N/A$6.00139.04% UpsideCYTHCyclo Therapeutics 0.00N/AN/AN/AVTGNVistaGen Therapeutics 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest CYTH, VTGN, CELU, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025ABOSAcumen PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $9.008/18/2025CELUCelularityWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageModerate Buy$6.006/18/2025VTGNVistaGen TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform6/17/2025ABOSAcumen PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/ACELUCelularity$44.59M1.35N/AN/A$0.37 per share6.78CYTHCyclo Therapeutics$870.73K27.24N/AN/A$0.21 per share3.43VTGNVistaGen Therapeutics$490K216.64N/AN/A$2.44 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$2.28N/AN/AN/AN/A-81.39%-61.96%11/11/2025 (Estimated)CELUCelularity-$57.89M-$3.18N/A∞N/A-165.22%-564.17%-56.34%11/5/2025 (Estimated)CYTHCyclo Therapeutics-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/AVTGNVistaGen Therapeutics-$51.42M-$1.78N/AN/AN/A-6,777.08%-74.06%-64.10%11/6/2025 (Estimated)Latest CYTH, VTGN, CELU, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q1 2025CELUCelularityN/A-$1.02N/A-$1.02N/A$5.74 million8/12/2025Q2 2025ABOSAcumen Pharmaceuticals-$0.54-$0.68-$0.14-$0.68N/AN/A8/7/2025Q1 2026VTGNVistaGen Therapeutics-$0.47-$0.47N/A-$0.47$0.22 million$0.24 million6/17/2025Q4 2025VTGNVistaGen Therapeutics-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.265.975.97CELUCelularity4.070.380.28CYTHCyclo TherapeuticsN/A0.170.16VTGNVistaGen TherapeuticsN/A5.985.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%CELUCelularity19.02%CYTHCyclo Therapeutics68.55%VTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals7.10%CELUCelularity22.10%CYTHCyclo Therapeutics29.78%VTGNVistaGen Therapeutics2.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million56.27 millionOptionableCELUCelularity22023.95 million18.66 millionOptionableCYTHCyclo Therapeutics932.92 million23.12 millionNo DataVTGNVistaGen Therapeutics4030.68 million29.81 millionOptionableCYTH, VTGN, CELU, and ABOS HeadlinesRecent News About These CompaniesVistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety TrialSeptember 2 at 6:35 AM | sg.finance.yahoo.comWhile institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) benefited from last week's 11% gain, retail investors stood to gain the mostAugust 17, 2025 | finance.yahoo.comVistaGen Therapeutics (NASDAQ:VTGN) Rating Increased to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | msn.comVistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Meets EstimatesAugust 10, 2025 | marketbeat.comVistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...August 8, 2025 | finance.yahoo.comVistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comQ1 2026 Vistagen Therapeutics Inc Earnings Call TranscriptAugust 8, 2025 | gurufocus.comVistagen (VTGN) Q1 R&D Expense Jumps 54%August 7, 2025 | fool.comVistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue EstimatesAugust 7, 2025 | zacks.comVistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate UpdateAugust 7, 2025 | businesswire.comVistaGen Therapeutics Q1 2026 Earnings PreviewAugust 6, 2025 | msn.comVistaGen Therapeutics (VTGN) to Release Earnings on ThursdayAugust 2, 2025 | marketbeat.comVistagen to Present at the BTIG Virtual Biotechnology ConferenceJuly 24, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comStifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 DelayJuly 3, 2025 | msn.comVTGN Vistagen Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comVistagen Appoints Elissa Cote as Chief Corporate Development OfficerJune 25, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call TranscriptJune 22, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTH, VTGN, CELU, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.36 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.36 -0.01 (-0.37%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Celularity NASDAQ:CELU$2.55 -1.39 (-35.28%) Closing price 04:00 PM EasternExtended Trading$2.64 +0.10 (+3.73%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Cyclo Therapeutics NASDAQ:CYTHCyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.VistaGen Therapeutics NASDAQ:VTGN$3.52 +0.18 (+5.39%) Closing price 04:00 PM EasternExtended Trading$3.52 0.00 (-0.14%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Alphabet’s Resurgence: It's Now a Clear Market Leader Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
